A study analyzing liver biopsy samples from MAFLD patients showed a 30% decrease in CYP3A4 activity during the simple fatty lesion stage and a 50% decrease during the NASH stage, while the CYP2E1 activity increased by 2.5 times during the NASH stage [25]. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatohepatitis.